Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib von Reichardt, P., Blay, J.-Y., Gelderblom, H., Schlemmer, M., Demetri, G.D., Bui-Nguyen, B., McArthur, G.A., Yazji, S., Hsu, Y., Galetic, I., Rutkowski, P.

Volltext

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL) von Lee, H., Choi, M., Siddiqi, T., Rhodes, J., Wierda, W., Isufi, I., Tuscano, J., Lamanna, N., Subbiah, S., Koff, J., Leslie, L., Goldenberg, A., Chung, G., Breitmeyer, J., Yazji, S., Shih, T., Wang, M., Jamieson, C., Kipps, T.

Volltext

Assessing the thermoelectric properties of single InSb nanowires: the role of thermal contact resistance von Yazji, S, Swinkels, M Y, De Luca, M, Hoffmann, E A, Ercolani, D, Roddaro, S, Abstreiter, G, Sorba, L, Bakkers, E P A M, Zardo, I

Volltext

Nisin production conditions optimization and its effect on Bacillus cereus and Listeria monocytogenes von Malas, B, Mohamad, M, Yazji, S

Volltext

Local modification of GaAs nanowires induced by laser heating von Yazji, S, Zardo, I, Soini, M, Postorino, P, Fontcuberta i Morral, A, Abstreiter, G

Volltext

P1154: STUDY ZILO‐301: A PHASE 3, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTOR... von Yazji, S., Hamburger, S., Wang, Y., Yavrom, S., Pietrofeso, A., Bliss, R., Breitmeyer, J. B., Dreyling, M., Wang, M.

Volltext

PP-149 GLUCOSE LEVEL IN PATIENTS WITHIN RECENT ACUTE CORONARY SYNDROME WHO UNDERGO CORONARY ANGIOGRAPHY von Habıb, M, Yazji, S, Khozundar, O

Volltext

PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-... von Mahalingam, D, Patel, M, Sachdev, J, Hart, L, Halama, N, Ramanathan, R, Sarantopoulos, J, Liu, X, Yazji, S, Jaeger, D, Adib, D, Kerschbaumer, R, Yoon, M, Manzur, G, Starodub, A, Sivarajan, K, Wertheim, M, Thambi, P, Jones, M, Goel, S, Nemunaitis, J, Tsimberidou, A

Volltext

Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes von YAZJI, S, GILES, F. J, TSIMBERIDOU, A-M, ESTEY, E. H, KANTARJIAN, H. M, O'BRIEN, S. A, KURZROCK, R

Volltext

Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas von RODRIGUEZ, Jose, MUNSELL, Mark, ROMAGUERA, Jorge, CABANILLAS, Fernando F, CHAMPLIN, Richard E, KHOURI, Issa F, YAZJI, Salim, HAGEMEISTER, Fredrick B, YOUNES, Anas, ANDERSSON, Borje, GIRALT, Sergio, GAJEWSKI, James, DE LIMA, Marcos, COURIEL, Daniel

Volltext

The spectrum of β-thalassemia mutations in Gaza Strip, Palestine von Sirdah, Mahmoud M., Sievertsen, Jürgen, Al-Yazji, Mansour S., Tarazi, Issa S., Al-Haddad, Ramy M., Horstmann, Rolf D., Timmann, Christian

Volltext

Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin’s lymphoma von Hosing, C., Munsell, M., Yazji, S., Andersson, B., Couriel, D., de Lima, M., Donato, M., Gajewski, J., Giralt, S., Körbling, M., Martin, T., Ueno, N. T., Champlin, R.E., Khouri, I.F.

Volltext

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 von Lee, H, Choi, M, Siddiqi, T, Rhodes, J, Wierda, W, Isufi, I, Tuscano, J, Lamanna, N, Subbiah, S, Koff, J, Leslie, L, Goldenberg, A, Chung, G, Breitmeyer, J, Yazji, S, Shih, T, Wang, M, Jamieson, C, Kipps, T

Volltext

P1.10A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue von Thiele, M, Schinagl, A, Douillard, P, Barak, H, Adib, D, Yazji, S, Scheiflinger, F, Kerschbaumer, R

Volltext

A fully human anti-oxMIF antibody penetrates colorectal cancer metastases and accumulates in cancer tissue von Thiele, M., Schinagl, A., Douillard, P., Barak, H., Adib, D., Yazji, S., Scheiflinger, F., Kerschbaumer, R.

Volltext

395 POSTER Phase I study of XL844, a novel Chk1 and Chk2 kinase inhibitor, in combination with gemcitabine in patients with advanced malignancies von Tse, A, Yazji, S, Naing, A, Matthews, D, Schwartz, G, Lawhorn, K, Kurzrock, R

Volltext

383 POSTER A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors von Schwartz, G.K, Yazji, S, Mendelson, D.S, Dickson, M.A, Johnston, S.H, Wang, E.W, Shannon, P, Pace, L, Gordon, M.S

Volltext

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib von Wagner, A.J, Yazji, S, Morgan, J.A, Choy, E, George, S, Hohos, M, O'Mara, M, Demetri, G.D

Volltext

Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study von Mahalingam, D., Patel, M.R., Sachdev, J.C., Hart, L.L., Halama, N., Ramanathan, R.K., Sarantopoulos, J., Liu, X., Yazji, S., Jäger, D., Yoon, M., Manzur, G.Ç, Adib, D., Kerschbaumer, R., Tsimberidou, A.

Volltext

PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5... von Mahalingam, D., Patel, M., Sachdev, J., Hart, L., Halama, N., Ramanathan, R., Sarantopoulos, J., Liu, X., Yazji, S., Jäger, D., Adib, D., Kerschbaumer, R., Yoon, M., Manzur, G., Starodub, A., Sivarajan, K., Wertheim, M., Thambi, P., Jones, M., Goel, S., Nemunaitis, J., Tsimberidou, A.

Volltext